Warnings, Columns-Drugs & Supplements, January 2006
January 20, 2006
Elidel and Protopic Labels Updated to Include Possible Cancer Risk WASHINGTON, D.C. - The Food and Drug Administration recently approved updated labels for eczema drugs Elidel and Protopic to include 'black box' warnings risk of cancer associated with the topical ointments. The FDA said on Jan. 19 that the boxed warning and medication guide will be distributed with Novartis Corp.'s Elidel Cream (pimecrolimus) and Astellas' Protopic Ointment (tacrolimus) to help ensure that patients are aware of the cancer risk. The new labels also clarify that these drugs are recommended for use as second-line treatments, the …
UPCOMING CONFERENCES
HarrisMartin's Webinar Series: Water Contamination Litigation Presented by EisnerAmperMay 06, 2025
HarrisMartin's Mass Tort Settlements Conference - Sponsored by MilestoneJune 25, 2025 - Buffalo, NY
The Westin Buffalo
|